Oxford BioMedica Announces Lentiviral Vector Development and Manufacturing Collaboration
Oxford BioMedica plc announced that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford BioMedica’s LentiVector® gene delivery technology.
Under the terms of the agreement, Oxford BioMedica will also provide certain process development services and expects to receive between £2.5 million and £4 million from Novartis over the next 12 months.
Oxford BioMedica will be responsible for manufacturing several batches of a lentiviral vector encoding CTL019 technology. This vector will be used to transduce patients’ immune cells (T-cells) in an ex vivo process before they are re-infused into patients. CTL019 targets a protein called CD19 that is associated with a number of B-cell malignancies including chronic lymphocytic leukemia, B-cell acute lymphocytic leukaemia and diffuse large B-cell lymphoma.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.